Optimizing dose and administration regimen of a high-relaxivity contrast agent for myocardial MRI late gadolinium enhancement

Università degli Studi di Milano, Dipartimento di Scienze Medico-Chirurgiche, Milan, Italy.
European journal of radiology (Impact Factor: 2.37). 10/2011; 80(1):96-102. DOI: 10.1016/j.ejrad.2010.06.040
Source: PubMed


To investigate the time-course of late gadolinium enhancement of infarcted myocardium using gadobenate dimeglumine at different dosages and administration regimens.
After institutional review board approval and informed consent, we studied 13 patients (aged 63±11 years) with chronic myocardial infarction. They underwent two gadobenate dimeglumine-enhanced MR examinations (interval 24-48 h) using short-axis inversion-recovery gradient-echo sequences, with the following two different protocols, in randomized order: 0.05 mmol/kg and imaging at the 2.5th, 5th, 7.5th and 10th minute plus 0.05 mmol/kg and imaging at the 12.5th, 15th, 17.5th and 20th minute; the same as before but using 0.1 mmol/kg for both contrast injections. Contrast-to-noise ratios (CNRs) between infarcted myocardium, non-infarcted myocardium and left ventricle cavity were calculated for each time-point (2.5-min steps). Friedman ANOVA was used for comparing the CNR time-course; Wilcoxon test for comparing CNR at the 10th and the 20th minute.
The CNR between infarcted and non-infarcted myocardium obtained at the 20th minute with 0.05 plus 0.05 mmol/kg resulted significantly higher than that obtained at the 10th minute with 0.05 mmol/kg (P=0.033) while not significantly different from that obtained at the 10th (0.1mm/kg) or at the 20th minute with 0.1 plus 0.1 mmol/kg. The CNR between infarcted myocardium and the left ventricle cavity obtained at the 20th minute with 0.05 plus 0.05 mmol/kg resulted significantly higher than all other measured values (P≤0.017).
Using gadobenate dimeglumine, 0.05 plus 0.05 mmol/kg allows for a higher CNR between infarcted myocardium and the left ventricle cavity allowing for reliable assessment of the sub-endocardial infarctions.

Download full-text


Available from: Francesco Secchi, Dec 31, 2014
17 Reads
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: A unique biomineralization approach was developed to synthesize gadolinium-based hybrid (GH) nanoparticles for effective blood pool contrast agents. This approach is bioinspired, environmentally benign, and straightforward. As-prepared GH nanoparticles are biocompatible and well stable in serum. They exhibit much higher longitudinal relaxivity and transverse relaxivity in water (r1 and r2 values of 15.0 and 19.7 s−1 per mM of Gd3+, respectively) than those measured for Gd–DTPA solution (r1 and r2 values of 3.7 and 4.6 s−1 per mM of Gd3+, respectively). In vivo T1-weighted magnetic resonance imaging (MRI) in living mice shows that the GH nanoparticles have an intravascular half-life up to 1 h, much longer than that of Gd–DTPA (about 10 min). As the GH nanoparticles were found to be cleared gradually via hepatobiliary (HB) processing, they can also serve as ideal candidates for liver specific MR contrast agents. In particular, these GH nanoparticles are bioinspired and environmentally benign, therefore promising for medical imaging applications.
    Journal of Materials Chemistry 07/2012; 22(29):14494-14501. DOI:10.1039/C2JM30629H · 7.44 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Nanoclusters of superparamagnetic iron oxide nanoparticles (SPION) are developed for liver-specific magnetic resonance imaging (MRI) by a unique synthesis route. The process is efficient, environmentally benign, and straight forward within five minutes. The clustering effect is triggered in the presence of bovine serum albumin (BSA) aqueous phase under ultrasonication condition. The hydrophobic SPION are densely self-assembled into BSA/SPION hybrid nanoclusters with a uniform size of ca. 86 nm. The as-prepared BSA/SPION hybrid nanoclusters are found to be biocompatible and stable. They exhibit high transverse relaxivity and longitudinal relaxivity in water (r2 and r1 values are 600.8 and 4.3 s-1 per mM of Fe3+, respectively). In vivo T2-weighted MRI shows excellent enhancement in liver with an imaging time-window up to 48 hours. In vivo biodistribution study indicates a gradual excretion of the nanoclusters via hepatobiliary (HB) processing. No toxicity is observed in the in vivo and ex vivo experiments. The BSA/SPION hybrid nanoclusters present great potential in MRI as the liver-specific contrast agents (CAs).
    ACS Applied Materials & Interfaces 11/2012; 4(12). DOI:10.1021/am301301f · 6.72 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Multi-modal imaging based on multifunctional nanoparticles is a promising alternative approach to improve the sensitivity of early cancer diagnosis. In this study, highly upconverting fluorescence and strong relaxivity rare-earth nanoparticles coated with paramagnetic lanthanide complex shells and polyethylene glycol (PEGylated UCNPs@DTPA-Gd(3+)) are synthesized as dual-modality imaging contrast agents (CAs) for upconverting fluorescent and magnetic resonance dual-modality imaging. PEGylated UCNPs@DTPA-Gd(3+) with sizes in the range of 32-86 nm are colloidally stable. They exhibit higher longitudinal relaxivity and transverse relaxivity in water (r1 and r2 values are 7.4 and 27.8 s(-1) per mM Gd(3+), respectively) than does commercial Gd-DTPA (r1 and r2 values of 3.7 and 4.6 s(-1) per mM Gd(3+), respectively). They are found to be biocompatible. In vitro cancer cell imaging shows good imaging contrast of PEGylated UCNPs@DTPA-Gd(3+). In vivo upconversion fluorescent imaging and T1-weighted MRI show excellent enhancement of both fluorescent and MR signals in the livers of mice administered PEGylated UCNPs@DTPA-Gd(3+). All the experimental results indicate that the synthesized PEGylated UCNPs@DTPA-Gd(3+) present great potential for biomedical upconversion of fluorescent and magnetic resonance dual-modality imaging applications.
    Nanotechnology 04/2013; 24(17):175101. DOI:10.1088/0957-4484/24/17/175101 · 3.82 Impact Factor
Show more